MBX Biosciences, Inc. MBX Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -25.7%— | -27.8%— | -24.4%— | —— | —— | |
| Return on assets | -24.8%— | -26.6%+8.5pp | -23.6%— | —— | —— | |
| Return on invested capital | -33%— | -39%— | -59.8%— | —— | —— | |
| Liquidity | ||||||
| Current ratio | 30.8×+7.5× | 24.6×+0.4× | 33×+7.2× | 19.5×— | 23.3×— | |
| Quick ratio | 30.8×+7.5× | 24.6×+0.4× | 33×+7.2× | 19.5×— | 23.3×— | |
| Cash ratio | 3.1×+0.3× | 4.9×+0.4× | 18.5×+6.3× | 3.4×— | 2.9×— | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×— | 0×— | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×— | 0×— | |
| Per Share | ||||||
| Book value per share | $9.40+33.4% | $10.11-58.2% | $11.33-72.8% | $6.55+108% | $7.05+110% | |
| Valuation | ||||||
| Market capitalization | $1.42B+475% | $1.42B+130% | $782.52M— | $369.34M— | $246.67M— | |
| Enterprise value | $1.37B+533% | $1.34B+137% | $560.02M— | $330.21M— | $216.9M— | |
| Price / book | 3.2×+2.2× | 3.8×+1.4× | 2×— | 1.7×— | 1×— | |
| Free cash flow yield | -5.6%+21.6pp | -5.8%+3.2pp | -10.1%— | -19.4%— | -27.3%— | |
| Earnings yield | -6.1%+23.7pp | -6.1%+3.9pp | -10.3%— | -20.9%— | -29.8%— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do MBX Biosciences, Inc.'s ratios come from?
- Every ratio is computed from MBX Biosciences, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.